ACH
ORIC icon

ArrowMark Colorado Holdings’s Oric Pharmaceuticals ORIC Stock Holding History

ArrowMark Colorado Holdings’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.31M Sell
582,875
-377,642
-39% -$3.42M 0.26% 153
2026
Q1 		$12.2M Sell
960,517
-103,252
-10% -$1.17M 0.32% 94
2025
Q4 		$8.7M Sell
1,063,769
-33,728
-3% -$388K 0.19% 152
2025
Q3 		$13.2M Sell
1,097,497
-180,957
-14% -$1.9M 0.24% 109
2025
Q2 		$13M Sell
1,278,454
-67,735
-5% -$455K 0.23% 110
2025
Q1 		$7.51M Sell
1,346,189
-49,163
-4% -$430K 0.12% 148
2024
Q4 		$11.3M Buy
1,395,352
+40,844
+3% +$375K 0.15% 126
2024
Q3 		$13.9M Buy
1,354,508
+80,986
+6% +$801K 0.18% 118
2024
Q2 		$9M Sell
1,273,522
-237,339
-16% -$2.12M 0.11% 148
2024
Q1 		$20.8M Sell
1,510,861
-222,958
-13% -$2.65M 0.23% 97
2023
Q4 		$16M Buy
1,733,819
+83,863
+5% +$606K 0.18% 111
2023
Q3 		$9.98M Buy
1,649,956
+232,083
+16% +$1.9M 0.12% 138
2023
Q2 		$11M Buy
1,417,873
+1,162,141
+454% +$6.6M 0.12% 141
2023
Q1 		$1.46M Sell
255,732
-267,426
-51% -$1.4M 0.02% 238
2022
Q4 		$3.08M Sell
523,158
-20,654
-4% -$69.7K 0.04% 220
2022
Q3 		$1.74M Sell
543,812
-739,346
-58% -$2.96M 0.02% 252
2022
Q2 		$5.75M Hold
1,283,158
– – 0.07% 210
2022
Q1 		$6.85M Sell
1,283,158
-616,233
-32% -$5.55M 0.06% 224
2021
Q4 		$27.9M Buy
1,899,391
+649,684
+52% +$10.1M 0.22% 106
2021
Q3 		$26.1M Buy
1,249,707
+227,809
+22% +$4.62M 0.2% 115
2021
Q2 		$18.1M Sell
1,021,898
-4,885
-0.5% -$107K 0.14% 135
2021
Q1 		$25.2M Sell
1,026,783
-26,096
-2% -$825K 0.19% 113
2020
Q4 		$35.6M Buy
1,052,879
+57,497
+6% +$1.65M 0.28% 94
2020
Q3 		$24.9M Buy
995,382
+733,604
+280% +$17.5M 0.24% 95
2020
Q2 		$8.83M Buy
+261,778
New +$8.36M 0.09% 156

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ArrowMark Colorado Holdings's ORIC Position: Q2 2026 in Review

ArrowMark Colorado Holdings reduced its Oric Pharmaceuticals (ORIC) stake by 39% in Q2 2026, selling an estimated $3.42M and leaving 582,875 shares worth $6.31M. The position accounts for 0.26% of the portfolio, ranked #153.

ArrowMark Colorado Holdings first reported a position in ORIC in Q2 2020 and has held it in 25 quarters since. The position peaked at $35.6M in Q4 2020. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • ArrowMark Colorado Holdings held 582,875 shares of Oric Pharmaceuticals worth $6.31M as of Q2 2026.
  • ArrowMark Colorado Holdings sold 377,642 Oric Pharmaceuticals shares in Q2 2026, an estimated $3.42M.
  • Oric Pharmaceuticals made up 0.26% of ArrowMark Colorado Holdings's portfolio in Q2 2026, its #153 holding.
  • ArrowMark Colorado Holdings first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • ArrowMark Colorado Holdings's Oric Pharmaceuticals position peaked at $35.6M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.